139 Ces Urol 2024; 28(3): 133–140 PŘEHLEDOVÉ ČLÁNKY ZÁVĚR Dostupná data potvrzují nízké, ale reálné riziko ovliv‑ nění kognitivního výkonu a rozvoje demence při dlouhodobé expozici anticholinergikům používa‑ ným v léčbě OAB. Vždy bychom proto měli pečlivě zvažovat poměr mezi očekávaným benefitem a po‑ tenciálními riziky v případě konkrétního pacienta. LITERATURA 1. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011; 59(8): 1477–1483. 2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010; 21(1): 5–26. 3. Peyronnet B, Mironska E, Chapple C, et al. A Comprehensive Review of Overactive Bladder Pathophys‑ iology: On the Way to Tailored Treatment. Eur Urol. 2019; 75(6): 988–1000. 4. Nambiar AK, Arlandis S, Bø K, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022; 82(1): 49–59. 5. He W, Huang G, Cui W, et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5): 535–563. 6. Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. Neurourol Urodyn. 2019; 38(2): 525–534. 7. Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011 Feb 23; 6(2): e16718. 8. Kim YJ, Tae BS, Bae JH. Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. Int Neurourol J. 2020; 24(3): 231–240. 9. Morley JE, Morris JC, Berg-Weger M, et al. Brain health: the importance of recognizing cognitive im‑ pairment: an IAGG consensus conference. J Am Med Dir Assoc. 2015; 16(9): 731–739. 10. Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 2019; 15(1): 1–7. 11. Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol. 2011; 70(3): 418–426. 12. Tiwari P, Dwivedi S, Singh MP, Mishra R, Chandy A. Basic and modern concepts on cholinergic re‑ ceptor: A review. Asian Pac J Trop Dis. 2013; 3(5): 413–420. 13. Lebois EP, Thorn C, Edgerton JR, Popiolek M, Xi S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer’s disease. Neuropharmacology. 2018; 136(Pt C): 362–373. 14. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic ace‑ tylcholine receptors. Pharmacol Rev. 1998; 50(2): 279–290. 15. Brann MR, Ellis J, Jørgensen H, Hill-Eubanks D, Jones SV. Muscarinic acetylcholine receptor subtypes: localization and structure/function. Prog Brain Res. 1993; 98: 121–127. 16. Messer WS Jr, Bohnett M, Stibbe J. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci Lett. 1990; 116(1–2): 184–189. 17. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5): 565–78. 18. Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dys‑ function with overactive bladder medications. Int Urogynecol J. 2021; 32(10): 2693–2702.
RkJQdWJsaXNoZXIy NDA4Mjc=